8^th Euro Global Diabetes Summit and Medicare Expo November 03-05, 2015 Valencia, Spain

OMICS International invites Diabetes expertise, researchers, professors, scientific communities, therapists, counselors, delegates, students, business professionals and executives to attend the 8^th Euro Global Diabetes Summit and Medicare Expo which is going to be held on November 03-05, 2015 at Valencia, Spain. OMICS International Organizes organizes 1000+ Global events inclusive of 300+ Conferences every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 500+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

For more conferences, please visit Conference Series

Prevalence of diabetes is increasing among all ages in  Europe, mostly due to increases in overweight and obesity, unhealthy diet and physical inactivity. There are about 60 million people with diabetes in the European Region, or about 10.3% of men and 9.6%  of women aged 25 years and over.

Worldwide, high blood glucose kills about 3.4 million people annually. Almost 80% of these deaths occur in low- and middle-income countries, and almost half are people aged less than 70 years. WHO projects diabetes deaths will double between 2005 and 2030.

Track 1: Complications associated with Diabetes

Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin, or both. Patients with high blood sugar will typically experience frequent urination, they will become increasingly thirsty and hungry .The term diabetes mellitus describes several diseases of abnormal carbohydrate metabolism that are characterized by hyperglycemia. It is associated with a relative or absolute impairment in insulin secretion, along with varying degrees of peripheral resistance to the action of insulin. They are derived after doing many clinical trials on animal models. Every few years, the diabetes community reevaluates the current recommendations for the classification, diagnosis, and screening of diabetes, reflecting new information from research and clinical practice which in turns help in understanding current prevention and treatment options and cost effectiveness in treatment and prevention of Diabetes. People with type1 and type2 diabetes have an increased risk of developing a number of serious health problems. Consistently high blood glucose levels can lead to serious diseases affecting the Macro vascular (Coronary artery diseases, cardiomyopathy and stroke) and micro vascular (Retinopathy, neuropathy and nephropathy) complications. In addition, people with diabetes also have a higher risk of developing infections. In almost all high-income countries, diabetes is a leading cause of cardiovascular disease, blindness, kidney failure, and lower limb amputation. Maintaining blood glucose levels, blood pressure, and cholesterol at or close to normal can help delay or prevent diabetes complications. Hypoglycemia and Hyperglycemia are the other two factors are the two major complications of diabetes where hyperglycemia is an acute complication sharing many symptoms and hypoglycemia is an acute complication of several diabetes treatments. Glycosylated hemoglobin is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. It is formed in a non-enzymatic glycation pathway by hemoglobin's exposure to plasma glucose.

Track 2: Genetics of Diabetes

Diabetes constitutes a major public health problem. Although substantial progress has been made in defining the genetics of metabolic syndrome risk for specific subtypes of diabetes (e.g., maturity-onset diabetes of the young), the majority of genetic risk of diabetes (for type 1 and type 2) remain unresolved. This review focuses on the current knowledge of the genetic basis of diabetes and its complications, specifically diabetic nephropathy (DN), recent advances in genetics of diabetes, diabetes in ethnic groups, genetic lifestyle interactions and understanding the genetics of Diabetes. Ultimately, identification of genes that contribute to risk (or protection) of diabetes and its complications will allow identification of patients who have diabetes and are at risk and targeted treatment/interventional strategies. Diabetic amyotrophy is a disabling illness that is distinct from other forms of diabetic neuropathy.

Track 3: Endocrinology: Disorders and Treatment                 

Endocrinology is the study of hormones and the treatment of hormone based diseases. The endocrine glands produce chemicals called hormones. These hormones are released into the blood stream and exert their action by stimulating other organs in the body. However, Clinical trials on endocrinology look at new ways to prevent, detect, or treat disease. The major endocrine glands are the thyroid, pancreas, parathyroid, adrenal, gonad and pituitary. The hormones from these glands regulate growth, metabolism, blood pressure, reproduction as well as many other necessary functions. Early Diagnosis and Treatment of Endocrine Disorders, written by a distinguished panel of clinical experts and research scientists, focuses on the early signs and symptoms of common endocrine diseases, surveys the clinical testing needed for a diagnosis, and concisely presents the best current recommendations for therapy. Pediatric endocrinology is a medical subspecialty that studies and treats conditions affecting physical growth and sexual development in children, as well as diabetes and other disorders of the endocrine (hormone) glands.

Track 4: Advanced Technologies for the Treatment of Diabetes

The concept of 'new technologies' for type 1 diabetes and new discovery and emerging therapies in type 2 diabetes has expanded in recent years at a rate that some might consider comparable to 'Moore’s Law', and the sheer number of new technologies entering into the type 1 diabetes marketplace is also growing at a remarkable rate. From the patient’s perspective, this is not only exciting but can lead to a sense of optimism. Technologies that today are growing commonplace (e.g. insulin pumps, rapid HbA1c monitoring, etc come under new therapeutic mechanisms of diabetes. Indeed, it could be argued that the major advances in type 1 diabetes care made within the last quarter of a century have come from technology rather than biology. At the same time, not all new technologies succeed (e.g. the Glucowatch), regardless of their purported promise. Both type 1 diabetes patients and their healthcare providers will soon see a series of further advanced medical technologies used in hospital and new technologies and novel therapies in diabetes treatment whose basis is tied to the notion of improving the lives of those with the disease.

Track 5: Diabetes Management

The main goal of diabetes management is, as far as possible, to restore carbohydrate metabolism to a normal state. To achieve this goal, individuals with an absolute deficiency of insulin require insulin replacement therapy, which is given through injections or an insulin pump. Insulin resistance, in contrast, can be corrected by dietary modifications and exercise. Other goals of diabetes management are to prevent or treat the many complications that can result from the disease itself and from its treatment. Healthy eating is a cornerstone of healthy living — with or without diabetes. But if you have diabetes, you need to know Impact of Food and Nutrition, impact of physical activity and yoga therapy in Diabetes Management. Diabetic foot complications result in huge costs for both society and the individual patients. Few reports on the health-economic consequences of diabetic foot infections have been published. Standards of medical care in Diabetes increased when compared to previous year.

Track 6: Emerging Focus in Diabetes Research

Diabetes is a common chronic disease that imposes considerable demands on the individual healthcare system. People with diabetes have a higher rate of cardiovascular disease than those without diabetes and are at increased risk for kidney failure, lower limb amputation and blindness. Obesity is a significant risk factor for diabetes and the prevalence of obesity in children and adults has dramatically increased in the past four decades. Diabetic dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. In order to investigate the bioinformatics tools and methodologies used to in diabetes research, at first, this was difficult to do because it did not have a preconceived idea about how the research would be organized and how bioinformatics tools would be described or identified in the research. To get started, we ran several cursory searches using basic search terms such as bioinformatics and diabetes (research) through several databases to see what types of articles were returned.  Diabesity can be defined as a metabolic dysfunction that ranges from mild blood sugar imbalance to full-fledged type 2 diabetes. A bolus dose is insulin that is specifically taken at meal times to keep blood glucose levels under control following a meal. 

Track 7: Transplantation of Diabetes

Getting a new heart, liver, kidney, lung, or other organ can save your life. Sometimes, it can also lead to type 2 diabetes. Many people can stop taking steroids after 6 months or so. This may solve the problem. If scientists can develop safe immunosuppressant’s that always work, then many people with type 1 diabetes may choose to have pancreas transplants. Until then, many doctors think islet transplants are a better option even after performing clinical trials on islet transplants . Islets are clusters of cells in the pancreas that make insulin. In people with type 1 diabetes, islet cells are destroyed. Only 1-2% of the pancreas is made up of islet cells. In pancreatic islet transplantation, cells are taken from a donor pancreas and transferred into another person. Once implanted, the new islets begin to make and release insulin. Researchers hope that islet transplantation will help people with type 1 diabetes live without daily injections of insulin. A transplant of the pancreas is usually reserved for those with serious complications. Pancreas transplants are most often done when a patient also receives a new kidney. The pancreas transplant adds little further risk in this situation and offers big benefits. However, transplant surgery is risky. Each person needs to carefully weigh the potential benefits and risks. Xenotransplantation for the treatment of type 1 diabetes is the transplantation of living cells, tissues or organs from one species to another. Such cells, tissues or organs are called xenografts or xenotransplants. A bolus dose is insulin that is specifically taken at meal times to keep blood glucose levels under control following a meal. A bolus dose is insulin that is specifically taken at meal times to keep blood glucose levels under control following a meal. Bolus insulin needs to act quickly and so short acting insulin or rapid acting insulin will be used where as Conventional insulinotherapy is a therapeutic regimen for treatment of diabetes mellitus which contrasts with the newer intensive insulin therapy.

Track 8: Diabetes Research in Clinical Practice

Novel therapeutic targets available for diabetes includes Incretin based therapies, oral therapeutic agents like secretagogues, beta cell regeneration & proliferation and stem cell therapies. Embryonic stem cell and fetal precursor cell transplantation therapies are the major stem cell therapies available for Diabetes. Apart from the above, various computational approaches in Diabetes management have been introduced recently which are playing an important role in identification of genes causing diabetes helping in Early Detection of Diabetes. These processes are also useful in studying the chemical etiologies of Diabetes uncovering various treatment prospects and model construction processes for survival prediction

Track 9: Computational Biology of Diabetes

Computational meta-analysis can link environmental chemicals to genes and proteins involved in human diseases, thereby elucidating possible etiologies. The recent rapid development of a variety of analytical platforms based on mass spectrometry and nuclear magnetic resonance have enabled identification of complex metabolic Syndrome phenotypes. Continued development of bioinformatics and analytical strategies has facilitated the discovery of causal links in understanding the pathophysiology of diabetes and its complications

Track 10:  Risk Factors and Related Diseases of Diabetes

Diabetes is always accompanied by a number of serious health issues. Consistent increase in blood glucose levels can lead to serious diseases affecting the vital organs of body like heart and blood vessels, eyes, kidneys, nerves and teeth. In almost all high-income countries, diabetes is a leading cause of cardiovascular disease like diabetic cardiomyopathy being one of the major risk factor, blindness, kidney failure, and lower limb amputation. Diabetic Retinopathy causes progressive damage to the retina in the patients with diabetes adding as the most vulnerable risk for the patient. Maintaining blood glucose levels, blood pressure, diabetic gastro paresis which has been reported to have the main cause as Diabetes Mellitus and cholesterol at or close to normal can help delay or prevent diabetes complications.